Emcure Pharmaceuticals Limited – FDA 483, May 15, 2026

From May 6 to May 15, 2026, the FDA inspected Emcure Pharmaceuticals Limited in Ahmedabad, India. The inspection resulted in a Form 483 identifying several significant lapses in manufacturing standards and quality control. Key issues included the firm"s failure to properly qualify equipment for its intended use; specifically, the company failed to test new vial configurations under "worst-case" conditions, which may have contributed to over 200 complaints regarding displaced vial stoppers. Additionally, the quality unit repeatedly closed market complaints regarding product ineffectiveness without thorough investigation, often citing missing batch numbers as a reason to forego further analysis. Sterile processing was also compromised. Investigators discovered residues and uneven surfaces in supposedly sterile cleanrooms and noted deficiencies in airflow studies designed to ensure product safety during manufacturing interventions. Further violations involved inadequate raw material testing and weak computer system controls that could allow analysts to preview test results before they were officially recorded, potentially compromising data integrity. These observations indicate that the firm"s procedures are not currently meeting federal requirements for quality and purity. Emcure Pharmaceuticals is required to provide a written response to the FDA detailing their corrective and preventive action plans to address these systemic failures. While these findings are not a final agency determination, they require immediate attention to avoid further regulatory action.